Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasmapheresis in DILI with Underlying Chronic Liver Disease
NCT06797011Phase 3Not yet recruiting
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Jan 2025
- Primary completion
- Jan 2026
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Liver Transplant free survival at 30 days. Planned start Jan 2025; status: not yet recruiting.
Beyond the preview
Go deeper on NCT06797011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06797011.